|Bid||66.00 x 20000|
|Ask||68.00 x 20000|
|Day's Range||66.00 - 66.00|
|52 Week Range||41.28 - 91.65|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
DAFNA Capital Management was founded in 1999 by Dr. Nathan Fischel, who is the fund’s CEO. Dr. Fischel is Pediatric Hematologist-Oncologist with a long career in medicine. He graduated from Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. He continued his […]
Deciphera Pharmaceuticals continued a two-day sprint Wednesday on excitement over a stomach cancer treatment, but at least one analyst far prefers rival biotech company Blueprint Medicines.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.98. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
# Blueprint Medicines Corp ### NASDAQ/NGS:BPMC View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding BPMC are favorable, with net inflows of $2.11 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.73% and -45.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of $1.66 per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.